Search Medical Condition
Please enter condition
Please choose location from dropdown

Tobacco Use Disorder Clinical Trials

A listing of Tobacco Use Disorder medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (158) clinical trials

The purpose of this study is to evaluate changes in exposure to selected harmful and potentially harmful substances related to tobacco/nicotine use when adult smokers switch from their usual brand of combustible cigarettes to an e-cigarette.  

Phase N/A

The purpose of this study is to estimate nicotine uptake and assess subjective effects during ad lib use sessions of an electronic nicotine delivery system with multiple flavors and nicotine concentrations as compared to an e-cigarette, conventional cigarettes, and nicotine gum in adult smokers ages 21 to 65.  

Phase

Examination of Low Wattage and High Wattage E-Cigarettes

The overall aim of the proposed study is to evaluate the effect of switching from conventional cigarettes to either a LWe or HWe on smoking behavior, product use patterns and continued use, as well as biomarkers of toxicant exposure and effects.

Phase N/A

Abuse Liability of Reduced Nicotine Content Cigarettes Within a Complex Tobacco Marketplace

Tobacco regulatory policies can have unanticipated consequences; therefore, methods that would permit prospective estimates of the effects of potential tobacco regulations are necessary for the development of tobacco regulatory science. The goal of this project is to experimentally assess how smokers purchase and consume reduced-nicotine cigarettes. In experiment 1, we ...

Phase N/A

Testing an Organizational Change Model to Address Smoking in Mental Healthcare

Despite an overall reduction in US smoking rates from >50% in the 1960s to about 20% by 2000, the rate of smoking among persons with a serious mental illness (SMI) remains 2-3 times greater than in the general population. Transforming the mental healthcare system to integrate and adhere to evidence-based ...

Phase N/A

Neural Mechanisms Associated With Risk of Smoking Relapse

Smoking is the greatest preventable cause of mortality and a significant economic burden. Even with the best available treatments, most smokers relapse within days or weeks after a quit attempt. Nicotine replacement therapy, the most widely used pharmacotherapy, yields end of treatment quit rates of <25% suggesting that managing nicotine ...

Phase N/A

Early Detection of COPD Patients in GOLD 0 (Smokers) Population

Even though the main risk factor for the development of chronic obstructive pulmonary disease (COPD) is smoking only in less than one third of the smokers the clinically manifest COPD will develop. The disease progressive nature with high disability and mortality especially in the final stages makes it plausible to ...

Phase N/A

Manipulating Tobacco Constituents in Male Menthol Smokers

The FDA has the regulatory authority to reduce, but not eliminate, nicotine from cigarettes. The Tobacco Products Scientific Advisory Committee has noted, among other things, that removal of menthol cigarettes from the marketplace would benefit the public health. A parent study (NCT02048852) examines the potential impact of these two regulatory ...

Phase N/A

Manipulating Tobacco Constituents in Female Menthol Smokers

Study is designed to address the following questions that have been outlined by the FDA as particular areas of interest: What are the factors, including menthol and other flavorings that influence the appeal of tobacco products to vulnerable populations: What is the impact of these factors on cessation, switching tobacco ...

Phase N/A

E-cigarettes Nicotine Inhaler and Blood Vessel Function

Participants will have an acute exposure on 4 occasions1) e-cigarette with nicotine, 2) e-cigarette without nicotine, 3) nicotine inhaler, 4) sham control and undergo ECG recording for heart rate variability, endothelial function measurement using ultrasound ("FMD") and blood tests for oxidative stress markers.

Phase N/A